Experience with host cell protein impurities in biopharmaceuticals
In the 40‐year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at levels high enough to be of concern. This article summarizes the industry experience in these cases where HCP impurities have been presented in...
Saved in:
| Published in | Biotechnology progress Vol. 34; no. 4; pp. 828 - 837 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.07.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In the 40‐year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at levels high enough to be of concern. This article summarizes the industry experience in these cases where HCP impurities have been presented in public forums and/or published. Regulatory guidance on HCP impurities is limited to advising that products be as pure as practical, with no specified numerical limit because the risk associated with HCP exposure often depends on the clinical setting (route of administration, dose, indication, patient population) and the particular impurity. While the overall safety and purity track record of the industry is excellent, these examples illustrate several important lessons learned about the kinds of HCPs that co‐purify with products (e.g., product homologs, and HCPs that react with product), and the kinds of clinical consequences of HCP impurities (e.g., direct biological activity, immunogenicity, adjuvant). The literature on industry experience with HCP impurities is scattered, and this review draws in to one reference documented examples where the data have been presented in meetings, patents, product inserts, or press releases, in addition to peer‐reviewed journal articles. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:828–837, 2018 |
|---|---|
| AbstractList | In the 40-year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at levels high enough to be of concern. This article summarizes the industry experience in these cases where HCP impurities have been presented in public forums and/or published. Regulatory guidance on HCP impurities is limited to advising that products be as pure as practical, with no specified numerical limit because the risk associated with HCP exposure often depends on the clinical setting (route of administration, dose, indication, patient population) and the particular impurity. While the overall safety and purity track record of the industry is excellent, these examples illustrate several important lessons learned about the kinds of HCPs that co-purify with products (e.g., product homologs, and HCPs that react with product), and the kinds of clinical consequences of HCP impurities (e.g., direct biological activity, immunogenicity, adjuvant). The literature on industry experience with HCP impurities is scattered, and this review draws in to one reference documented examples where the data have been presented in meetings, patents, product inserts, or press releases, in addition to peer-reviewed journal articles. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:828-837, 2018. In the 40‐year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at levels high enough to be of concern. This article summarizes the industry experience in these cases where HCP impurities have been presented in public forums and/or published. Regulatory guidance on HCP impurities is limited to advising that products be as pure as practical, with no specified numerical limit because the risk associated with HCP exposure often depends on the clinical setting (route of administration, dose, indication, patient population) and the particular impurity. While the overall safety and purity track record of the industry is excellent, these examples illustrate several important lessons learned about the kinds of HCPs that co‐purify with products (e.g., product homologs, and HCPs that react with product), and the kinds of clinical consequences of HCP impurities (e.g., direct biological activity, immunogenicity, adjuvant). The literature on industry experience with HCP impurities is scattered, and this review draws in to one reference documented examples where the data have been presented in meetings, patents, product inserts, or press releases, in addition to peer‐reviewed journal articles. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:828–837, 2018 In the 40‐year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at levels high enough to be of concern. This article summarizes the industry experience in these cases where HCP impurities have been presented in public forums and/or published. Regulatory guidance on HCP impurities is limited to advising that products be as pure as practical, with no specified numerical limit because the risk associated with HCP exposure often depends on the clinical setting (route of administration, dose, indication, patient population) and the particular impurity. While the overall safety and purity track record of the industry is excellent, these examples illustrate several important lessons learned about the kinds of HCPs that co‐purify with products (e.g., product homologs, and HCPs that react with product), and the kinds of clinical consequences of HCP impurities (e.g., direct biological activity, immunogenicity, adjuvant). The literature on industry experience with HCP impurities is scattered, and this review draws in to one reference documented examples where the data have been presented in meetings, patents, product inserts, or press releases, in addition to peer‐reviewed journal articles. © 2018 American Institute of Chemical Engineers Biotechnol. Prog. , 34:828–837, 2018 |
| Author | Zhu‐Shimoni, Judith Lin, Sansan Gunawan, Feny Vanderlaan, Martin Waerner, Thomas Van Cott, Kevin E. |
| Author_xml | – sequence: 1 givenname: Martin orcidid: 0000-0002-0763-5215 surname: Vanderlaan fullname: Vanderlaan, Martin email: sfmist@sbcglobal.net organization: Genentech, 1 DNA Way – sequence: 2 givenname: Judith surname: Zhu‐Shimoni fullname: Zhu‐Shimoni, Judith organization: Genentech, 1 DNA Way – sequence: 3 givenname: Sansan surname: Lin fullname: Lin, Sansan organization: Genentech, 1 DNA Way – sequence: 4 givenname: Feny surname: Gunawan fullname: Gunawan, Feny organization: Genentech, 1 DNA Way – sequence: 5 givenname: Thomas surname: Waerner fullname: Waerner, Thomas organization: Boehringer Ingelheim Pharma GmbH & Co. KG – sequence: 6 givenname: Kevin E. surname: Van Cott fullname: Van Cott, Kevin E. organization: University of Nebraska‐Lincoln |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29693803$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kEtLw0AUhQep2Icu_AMScKOL2DuPTJKlLfUBBUXqesjjhk5pHs4k1P57J7a6EFwd7uXjcPjGZFDVFRJySeGOArBp2jbmjkkBJ2REAwa-BM4HZBSFgfTDmEdDMrZ2AwARSHZGhiyW7gt8RGaLzwaNxipDb6fbtbeubetluN16jalb1JWny6YzutVoPXelum7WiSmTDLtWZ8nWnpPTwgVeHHNC3h8Wq_mTv3x5fJ7fL_2MxwB-QCMsCsETIQuOuczTmBVhTOMopSGKEHKWREJyIZAHUZYjp1QETIiYRgKx4BNyc-h1wz46tK0qte2XJhXWnVUMOMSMBlw69PoPuqk7U7l1ilFKIWRUho66PVCZqa01WKjG6DIxe0VB9WJVL1b1Yh17dWzs0hLzX_LHpAOmB2Cnt7j_v0nNVq9v35VfKfqDPw |
| CitedBy_id | crossref_primary_10_1002_btpr_3448 crossref_primary_10_1002_btpr_3128 crossref_primary_10_1016_j_chroma_2019_02_056 crossref_primary_10_1080_14789450_2024_2373707 crossref_primary_10_7554_eLife_78513 crossref_primary_10_1002_bit_27857 crossref_primary_10_1007_s12247_019_09412_5 crossref_primary_10_1016_j_ejpb_2024_114369 crossref_primary_10_1016_j_pep_2021_106004 crossref_primary_10_1002_btpr_3244 crossref_primary_10_1080_19420862_2021_1955432 crossref_primary_10_1016_j_chroma_2020_461237 crossref_primary_10_1016_j_jpba_2021_114537 crossref_primary_10_1080_19420862_2023_2213365 crossref_primary_10_1016_j_biotechadv_2020_107552 crossref_primary_10_1002_bit_27808 crossref_primary_10_1021_acs_analchem_1c00042 crossref_primary_10_1016_j_chroma_2023_464305 crossref_primary_10_1208_s12248_020_00440_5 crossref_primary_10_1021_acs_oprd_2c00327 crossref_primary_10_1002_pmic_202300172 crossref_primary_10_1002_bit_28112 crossref_primary_10_1016_j_seppur_2021_118358 crossref_primary_10_1002_bit_28678 crossref_primary_10_1016_j_jpha_2023_03_009 crossref_primary_10_1016_j_ijpharm_2023_123360 crossref_primary_10_1007_s00216_020_02796_1 crossref_primary_10_1016_j_ejps_2023_106597 crossref_primary_10_1016_j_ejps_2021_105980 crossref_primary_10_1016_j_copbio_2021_06_026 crossref_primary_10_1016_j_ijpharm_2020_119934 crossref_primary_10_1016_j_xphs_2021_08_024 crossref_primary_10_1080_19420862_2022_2135183 crossref_primary_10_1016_j_xphs_2024_05_013 crossref_primary_10_1016_j_procbio_2021_01_026 crossref_primary_10_1007_s11095_023_03649_z crossref_primary_10_1002_btpr_3424 crossref_primary_10_1002_bit_27559 crossref_primary_10_1002_elsc_202000104 crossref_primary_10_1002_bit_27514 crossref_primary_10_1080_19420862_2021_1955811 crossref_primary_10_1016_j_ejpb_2023_06_019 crossref_primary_10_1208_s12248_023_00852_z crossref_primary_10_1016_j_ijpharm_2023_122660 crossref_primary_10_1016_j_chroma_2022_463638 crossref_primary_10_1093_abt_tbac002 crossref_primary_10_1093_abt_tbad017 crossref_primary_10_1002_biot_202300068 crossref_primary_10_1016_j_coche_2018_08_001 crossref_primary_10_1208_s12248_020_00443_2 crossref_primary_10_1002_biot_202300261 crossref_primary_10_1002_cpt_1694 crossref_primary_10_1002_btpr_2788 crossref_primary_10_1038_s41597_020_00594_z crossref_primary_10_1016_j_jpba_2022_115089 crossref_primary_10_1002_btpr_2983 crossref_primary_10_1007_s00216_021_03648_2 crossref_primary_10_1007_s11095_024_03723_0 crossref_primary_10_1016_j_jpba_2023_115581 crossref_primary_10_1016_j_pep_2022_106113 crossref_primary_10_1016_j_jbiotec_2024_02_001 crossref_primary_10_1016_j_jpba_2024_116009 crossref_primary_10_2174_1389201024666230818112633 crossref_primary_10_1177_1759720X211002685 crossref_primary_10_1371_journal_pone_0265886 crossref_primary_10_1016_j_chroma_2022_463645 crossref_primary_10_1007_s11095_022_03381_0 |
| Cites_doi | 10.1021/pr300476w 10.1007/978-3-540-72167-3_1 10.1073/pnas.88.6.2236 10.1016/0014-5793(89)80590-3 10.1155/2016/7678901 10.1016/S0140-6736(07)60149-4 10.1016/j.jchromb.2009.03.042 10.1007/s10930-014-9550-5 10.1002/bit.25286 10.1002/mrd.20385 10.1002/bit.25327 10.1016/j.ab.2012.05.018 10.1056/NEJMoa1106469 10.1016/j.xphs.2016.02.022 10.1111/j.1742-4658.2005.04879.x 10.1002/bit.22982 10.1016/j.jim.2008.01.001 10.1002/bit.26360 10.1002/jps.24054 10.1002/btpr.2397 10.1002/prot.24388 10.1002/bit.22494 10.1136/thoraxjnl-2014-206719 10.1074/jbc.272.24.15270 10.1002/jps.24642 10.1016/j.xphs.2016.02.029 10.1016/j.chroma.2014.03.010 10.1111/j.1365-2516.2009.02039.x 10.1111/hae.12127 10.1016/0022-1759(86)90481-3 10.1007/s40259-013-0018-5 10.1002/bit.25158 10.1002/btpr.2455 10.1002/bit.25647 10.1016/0167-4838(92)90062-I 10.1042/BJ20090272 10.1016/j.biotechadv.2007.01.007 10.1002/btpr.50 10.1002/bit.23217 10.1002/biot.201100479 10.1128/JCM.00373-09 10.1111/j.1651-2227.1986.tb10357.x 10.1111/j.1538-7836.2005.01367.x 10.1074/jbc.M500765200 10.1056/NEJM199309023291001 10.1002/bit.22304 |
| ContentType | Journal Article |
| Copyright | 2018 American Institute of Chemical Engineers 2018 American Institute of Chemical Engineers. |
| Copyright_xml | – notice: 2018 American Institute of Chemical Engineers – notice: 2018 American Institute of Chemical Engineers. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QO 7T7 7U7 8FD C1K FR3 M7N P64 7X8 |
| DOI | 10.1002/btpr.2640 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Biotechnology Research Abstracts CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1520-6033 |
| EndPage | 837 |
| ExternalDocumentID | 10_1002_btpr_2640 29693803 BTPR2640 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- -~X .DC 05W 0R~ 1L6 1OB 1OC 1WB 23N 31~ 33P 3SF 3WU 4.4 52U 52V 53G 55A 5GY 5VS 66C 6J9 8-1 A00 A8Z AABXI AAESR AAEVG AAHHS AAIHA AANLZ AAONW AASGY AAXRX AAZKR ABCUV ABEFU ABHMW ABJNI ABQWH ABTAH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACJ ACMXC ACPOU ACPRK ACS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AGXLV AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN AZVAB BAANH BDRZF BFHJK BHBCM BLYAC BMXJE BNHUX BOGZA BRXPI C45 CS3 DCZOG DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EDH EJD EMOBN ESTFP F5P FEDTE FUBAC G-S GODZA HF~ HGLYW HHY HVGLF HZ~ I-F IHE ITG ITH IX1 JG~ KBYEO LATKE LEEKS LITHE LOXES LUTES LYRES MEWTI ML0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ NDZJH NNB O9- OIG OVD P2P P2W P4E PALCI QRW RIWAO RJQFR ROL RWI SAMSI SUPJJ SV3 TAE TEORI TN5 TUS W99 WBKPD WIH WIJ WIK WOHZO WSB WXSBR WYJ XV2 Y6R ZCA ZY4 ZZTAW ~02 ~KM ~S- CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7QO 7T7 7U7 8FD C1K FR3 M7N P64 7X8 |
| ID | FETCH-LOGICAL-c3900-518eff43a46f3ed6db92f79198b17e470d2a846344e358cde311452449184eef3 |
| IEDL.DBID | DR2 |
| ISSN | 8756-7938 |
| IngestDate | Sat Aug 17 01:20:12 EDT 2024 Thu Oct 10 16:17:07 EDT 2024 Fri Aug 23 00:26:27 EDT 2024 Wed Oct 16 00:51:21 EDT 2024 Sat Aug 24 00:59:14 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | clinical responses host cell proteins Chinese Hamster Ovary proteins impurities immunogenicity product stability |
| Language | English |
| License | 2018 American Institute of Chemical Engineers. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3900-518eff43a46f3ed6db92f79198b17e470d2a846344e358cde311452449184eef3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-0763-5215 |
| PMID | 29693803 |
| PQID | 2111072167 |
| PQPubID | 2034897 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2030921536 proquest_journals_2111072167 crossref_primary_10_1002_btpr_2640 pubmed_primary_29693803 wiley_primary_10_1002_btpr_2640_BTPR2640 |
| PublicationCentury | 2000 |
| PublicationDate | July/August 2018 |
| PublicationDateYYYYMMDD | 2018-07-01 |
| PublicationDate_xml | – month: 07 year: 2018 text: July/August 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Biotechnology progress |
| PublicationTitleAlternate | Biotechnol Prog |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2009; 47 1993; 329 2006; 73 2015; 70 2000; 48 1997; 272 2016; 2016 2016; 105 2014; 1340 2009; 877 2017; 114 2012; 11 2013; 19 1991; 88 2017; 33 2008; 24 2011; 365 2007; 25 2009; 15 2015; 12 1986; 91 2015; III 2005; 272 2007; 369 2012 2010 2009 2008 1996 2005 2014; 111 1999; 5 2014; 82 2016; 14 2012; 428 1995; 8 2005; 280 2011; 108 1986; 325 1992; 1159 1989; 244 2004; 17 2015; 112 2009; 420 2017 2016 2015 2014 2005; 3 2008; 333 2013 2012; 7 2009; 103 2014; 33 2009; 104 1998; 35 e_1_2_5_27_1 e_1_2_5_25_1 e_1_2_5_48_1 e_1_2_5_23_1 e_1_2_5_46_1 e_1_2_5_21_1 e_1_2_5_44_1 e_1_2_5_65_1 e_1_2_5_67_1 e_1_2_5_69_1 e_1_2_5_29_1 Shahrokh Z (e_1_2_5_74_1) 1995; 8 e_1_2_5_61_1 e_1_2_5_63_1 e_1_2_5_42_1 Tuohy VK (e_1_2_5_77_1) 2000; 48 e_1_2_5_38_1 e_1_2_5_17_1 e_1_2_5_36_1 e_1_2_5_59_1 e_1_2_5_9_1 Vanderlaan M (e_1_2_5_40_1) 2015; 12 e_1_2_5_11_1 e_1_2_5_34_1 e_1_2_5_57_1 e_1_2_5_7_1 e_1_2_5_13_1 e_1_2_5_32_1 e_1_2_5_55_1 e_1_2_5_5_1 e_1_2_5_3_1 e_1_2_5_19_1 e_1_2_5_70_1 e_1_2_5_72_1 e_1_2_5_30_1 e_1_2_5_53_1 e_1_2_5_51_1 Fischer SK (e_1_2_5_41_1) 2016 e_1_2_5_28_1 e_1_2_5_49_1 e_1_2_5_26_1 e_1_2_5_47_1 e_1_2_5_24_1 e_1_2_5_45_1 e_1_2_5_22_1 e_1_2_5_43_1 e_1_2_5_66_1 e_1_2_5_68_1 e_1_2_5_62_1 e_1_2_5_64_1 e_1_2_5_20_1 e_1_2_5_14_1 e_1_2_5_39_1 e_1_2_5_16_1 e_1_2_5_37_1 e_1_2_5_58_1 e_1_2_5_8_1 e_1_2_5_35_1 e_1_2_5_56_1 e_1_2_5_6_1 Wadhwa M (e_1_2_5_33_1) 1999; 5 e_1_2_5_12_1 e_1_2_5_54_1 e_1_2_5_4_1 e_1_2_5_2_1 e_1_2_5_18_1 Rosenberg AS (e_1_2_5_15_1) 2004; 17 Shahrokh Z (e_1_2_5_10_1) 2016; 14 Champion KMH (e_1_2_5_76_1) 2005 e_1_2_5_71_1 e_1_2_5_73_1 e_1_2_5_75_1 Harrison S (e_1_2_5_60_1) 1998; 35 e_1_2_5_31_1 e_1_2_5_52_1 e_1_2_5_50_1 |
| References_xml | – volume: 244 start-page: 487 year: 1989 end-page: 493 article-title: Human monocyte chemoattractant protein‐1 (MCP‐1). Full‐length‐cDNA cloning, expression in mitogen‐stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE publication-title: FEBS Lett. – year: 2009 – volume: 82 start-page: 300 year: 2014 end-page: 311 article-title: Is the bovine lysosomal phospholipase B‐like protein an amidase? publication-title: Proteins. – volume: 105 start-page: 1633 year: 2016 end-page: 1642 article-title: Polysorbates 20 and 80 degradation by Group XV lysosomal phospholipase A2 isomer X1 in monoclonal antibody formulations publication-title: J Pharm Sci. – volume: 48 start-page: 347 year: 2000 end-page: 351 article-title: Epitope spreading: a mechanism for progression of autoimmune disease publication-title: Archivum Immunologiae Et Therapiae Experimentalis. – volume: 108 start-page: 2759 year: 2011 end-page: 2764 article-title: Transforming growth factor‐β1 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells publication-title: Biotechnol Bioeng. – volume: 33 start-page: 666 year: 2017 end-page: 676 article-title: Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cells publication-title: Biotechnol Prog. – year: 2013 article-title: Managing unexpected events in the manufacturing of biologic medicines publication-title: BioDrugs. – volume: 365 start-page: 1088 year: 2011 end-page: 1098 article-title: Lebrikizumab treatment in adults with asthma publication-title: N Engl J Med. – volume: 272 start-page: 4858 year: 2005 end-page: 4867 article-title: The undecided serpin: the ins and outs of plasminogen activator inhibitor type 2 publication-title: FEBS J. – volume: 428 start-page: 150 year: 2012 end-page: 157 article-title: Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry publication-title: Anal Biochem. – volume: 8 start-page: 32 year: 1995 end-page: 38 article-title: Cellulose cleaving activity from detected in topical formulations of recombinant proteins publication-title: BioPharm. – volume: 420 start-page: 1 year: 2009 end-page: 16 article-title: Pathogen recognition in the innate immune response publication-title: Biochem J. – start-page: 21 year: 2013 end-page: 23 – year: 2014 – volume: 7 start-page: 1233 year: 2012 end-page: 1241 article-title: Studying host cell protein interactions with monoclonal antibodies using a high throughput protein A chromatography publication-title: Biotechnol J. – volume: 114 start-page: 2267 year: 2017 end-page: 2278 article-title: Proteomic analysis of host cell protein dynamics in the supernatant of Fc‐fusion protein‐producing CHO DG44 and DUXK‐B11 cell lines in batch and fed‐batch cultures publication-title: Biotechnol Bioeng. – volume: 2016 year: 2016 article-title: Characterization of IXINITY (Trenonacog Alpha), a recombinant factor IX with primary sequence corresponding to the threonine‐148 polymorph publication-title: Adv Hematol. – volume: 19 start-page: 619 year: 2013 end-page: 625 article-title: Product‐dependent anti‐Factor VIII antibodies publication-title: Haemophilia. – volume: 3 start-page: 1692 year: 2005 end-page: 1701 article-title: The promise and challenges of bioengineered recombinant clotting factors publication-title: J Thombosis Haemostat. – volume: 280 start-page: 16410 year: 2005 end-page: 16416 article-title: Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation publication-title: J Biol Chem. – volume: 1159 start-page: 319 year: 1992 end-page: 326 article-title: Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG publication-title: Biochem Biophys Acta. – volume: 70 start-page: 748 year: 2015 end-page: 756 article-title: Lebrikizumab in moderate‐to‐severe asthma: pooled data from two randomized placebo‐controlled studies publication-title: Thorax. – volume: III start-page: 56 year: 2015 end-page: 60 – volume: 15 start-page: 1027 year: 2009 end-page: 1031 article-title: Inhibitors in factor IX deficiency: a report of the ISTH‐SSC International FIX inhibitor registry (1997–2006) publication-title: Haemophilia. – year: 2016 article-title: Specific immune response to phospholipase B‐like2 protein, a host cell impurity in lebrikizumab clinical material publication-title: AAPS J. – volume: 104 start-page: 1132 year: 2009 end-page: 1141 article-title: Degradation of an Fc‐Fusion recombinant protein by host cell proteases. Identification of a CHO Cathepsin D protease publication-title: Biotechnol Bioeng. – start-page: 52 year: 2005 end-page: 57 article-title: Defining your product profile and maintaining control over it, Part 2: challenges of monitoring host cell protein impurities publication-title: Bioprocess Int. – volume: 111 start-page: 2367 year: 2014 end-page: 2379 article-title: Host cell protein testing by ELISAs and the use of orthogonal methods publication-title: Biotechnol Bioeng. – volume: 5 start-page: 1353 year: 1999 end-page: 1361 article-title: Immunogenicity of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) products in patients undergoing combination therapy with GM‐CSF publication-title: Clin Cancer Res. – volume: 25 start-page: 325 year: 2007 end-page: 331 article-title: Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes publication-title: Biotechnol Adv. – volume: 17 start-page: 34 year: 2004 end-page: 42 article-title: A risk‐based approach to immunogenicity concerns of therapeutic protein products publication-title: Biopharm Int. – volume: 105 start-page: 1657 year: 2016 end-page: 1666 article-title: Residual host cell protein promotes polysorbate 20 degradation in a sulfatase drug product leading to free fatty acid particles publication-title: J Pharm Sci. – volume: 33 start-page: 174 year: 2014 end-page: 183 article-title: Improved expression of recombinant human factor IX by co‐expression of GGCX, VKOR, and Furin publication-title: Protein J. – volume: 24 start-page: 1115 year: 2008 end-page: 1121 article-title: Host cell protein clearance during protein A chromatography: development of an improved column wash step publication-title: Biotechnol Prog. – volume: 47 start-page: 3427 year: 2009 end-page: 3434 article-title: Use of Toll‐like receptor assays to detect and identify microbial contaminants in biological products publication-title: J Clin Microbiol. – volume: 111 start-page: 904 year: 2014 end-page: 912 article-title: Identification and characterization of host cell protein product‐associated impurities in monoclonal antibody bioprocessing publication-title: Biotechnol Bioeng. – volume: 369 start-page: 275 year: 2007 end-page: 282 article-title: Thrombolysis with alteplase for acute ischeamic stroke in the safe implementation of thrombolysis in stroke‐monitoring study (SITS‐MOST): an observational study publication-title: Lancet. – start-page: 1 year: 2008 end-page: 20 article-title: Toll‐like receptors (TLRs) and their ligands publication-title: Handb Exp Pharmacol. – volume: 1340 start-page: 68 year: 2014 end-page: 78 article-title: Nonspecific interactions of chromatin with immunoglobulin G and Protein A, and their impact on purification performance publication-title: J Chrom A. – volume: 91 start-page: 213 year: 1986 end-page: 224 article-title: Immunoassay for the detection of proteins in recombinant DNA derived human growth hormone publication-title: J Immunol Meth. – volume: 33 start-page: 140 year: 2017 end-page: 145 article-title: Identification of an IgG CDR sequence contributing to co‐purification of the host cell proteinase Cathepsin D publication-title: Biotechnol Prog. – year: 1996 – volume: 877 start-page: 1543 year: 2009 end-page: 1552 article-title: Evicting hitchhiker antigens from purified antibodies publication-title: J Chrom B. – year: 2016 – volume: 111 start-page: 2170 year: 2014 end-page: 2182 article-title: CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO‐based protein production publication-title: Biotechnol Bioeng. – volume: 108 start-page: 977 year: 2011 end-page: 982 article-title: Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity publication-title: Biotechnol Bioeng. – year: 2010 – year: 2012 – volume: 88 start-page: 2236 year: 1991 end-page: 2240 article-title: Identification and purification to near homogeneity of the vitamin K‐dependent carboxylase publication-title: Proc Natl Acad Sci USA. – volume: 112 start-page: 2284 year: 2015 end-page: 2291 article-title: Host cell proteins in biotechnology‐derived products: a risk assessment framework publication-title: Biotechnol Bioeng. – year: 2014 article-title: Ester hydrolysis of Polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations publication-title: J Pharm Sci. – volume: 11 start-page: 5265 year: 2012 end-page: 5276 article-title: Proteomic analysis of chinese hamster ovary cells publication-title: J Proteome Res. – volume: 333 start-page: 1 year: 2008 end-page: 9 article-title: Recommendations on risk‐based strategies for detection and characterization of antibodies against biotechnology products publication-title: J Immunol Meth. – volume: 272 start-page: 15270 year: 1997 end-page: 15274 article-title: Secretion of human furin into mouse milk publication-title: J Biol Chem. – volume: 12 start-page: 18 year: 2015 end-page: 29 article-title: Hamster Phospholipase B‐Like 2 (PLBL2), a host cell protein impurity in CHO‐derived therapeutic monoclonal antibodies publication-title: BioProcess Int. – volume: 329 start-page: 673 year: 1993 end-page: 682 article-title: GUSTO Investigators. International randomized trial comparing four thrombolytic strategies for acute myocardial infarction publication-title: N Engl J Med. – volume: 35 start-page: 4 year: 1998 end-page: 10 article-title: The manufacturing process for recombinant factor IX publication-title: Semin Hematol. – volume: 325 start-page: 13 year: 1986 end-page: 18 article-title: Treatment of pituitary dwarfism with biosynthetic growth hormone publication-title: Acta Paediatr Scand (Suppl). – year: 2017 – volume: 73 start-page: 9 year: 2006 end-page: 19 article-title: Expression of serpin b6 serpins in germ and somatic cells of mouse gonads publication-title: Mol Reprod Dev. – year: 2015 article-title: Host cell proteins: the hidden side of biosimilarity assessment publication-title: J Pharm Sci. – volume: 103 start-page: 446 year: 2009 end-page: 458 article-title: Host cell proteins in biologics development: identification, quantitation, and risk assessment publication-title: Betechnol Bioeng. – volume: 14 start-page: 40 year: 2016 end-page: 51 article-title: Science, risks and regulations: current perspectives on host cell protein analysis and control publication-title: BioProcess Int. – year: 2013 – ident: e_1_2_5_14_1 doi: 10.1021/pr300476w – ident: e_1_2_5_51_1 – ident: e_1_2_5_29_1 doi: 10.1007/978-3-540-72167-3_1 – ident: e_1_2_5_57_1 doi: 10.1073/pnas.88.6.2236 – ident: e_1_2_5_65_1 – ident: e_1_2_5_50_1 doi: 10.1016/0014-5793(89)80590-3 – volume: 12 start-page: 18 year: 2015 ident: e_1_2_5_40_1 article-title: Hamster Phospholipase B‐Like 2 (PLBL2), a host cell protein impurity in CHO‐derived therapeutic monoclonal antibodies publication-title: BioProcess Int. contributor: fullname: Vanderlaan M – ident: e_1_2_5_63_1 doi: 10.1155/2016/7678901 – ident: e_1_2_5_48_1 – start-page: 52 year: 2005 ident: e_1_2_5_76_1 article-title: Defining your product profile and maintaining control over it, Part 2: challenges of monitoring host cell protein impurities publication-title: Bioprocess Int. contributor: fullname: Champion KMH – ident: e_1_2_5_24_1 doi: 10.1016/S0140-6736(07)60149-4 – ident: e_1_2_5_64_1 – volume: 14 start-page: 40 year: 2016 ident: e_1_2_5_10_1 article-title: Science, risks and regulations: current perspectives on host cell protein analysis and control publication-title: BioProcess Int. contributor: fullname: Shahrokh Z – ident: e_1_2_5_37_1 doi: 10.1016/j.jchromb.2009.03.042 – ident: e_1_2_5_56_1 doi: 10.1007/s10930-014-9550-5 – ident: e_1_2_5_4_1 – ident: e_1_2_5_19_1 doi: 10.1002/bit.25286 – ident: e_1_2_5_28_1 doi: 10.1002/mrd.20385 – ident: e_1_2_5_5_1 – ident: e_1_2_5_11_1 doi: 10.1002/bit.25327 – ident: e_1_2_5_13_1 doi: 10.1016/j.ab.2012.05.018 – ident: e_1_2_5_44_1 doi: 10.1056/NEJMoa1106469 – volume: 35 start-page: 4 year: 1998 ident: e_1_2_5_60_1 article-title: The manufacturing process for recombinant factor IX publication-title: Semin Hematol. contributor: fullname: Harrison S – ident: e_1_2_5_73_1 doi: 10.1016/j.xphs.2016.02.022 – ident: e_1_2_5_26_1 doi: 10.1111/j.1742-4658.2005.04879.x – ident: e_1_2_5_8_1 – volume: 8 start-page: 32 year: 1995 ident: e_1_2_5_74_1 article-title: Cellulose cleaving activity from E. coli detected in topical formulations of recombinant proteins publication-title: BioPharm. contributor: fullname: Shahrokh Z – ident: e_1_2_5_21_1 – ident: e_1_2_5_49_1 – ident: e_1_2_5_32_1 – ident: e_1_2_5_67_1 doi: 10.1002/bit.22982 – ident: e_1_2_5_17_1 doi: 10.1016/j.jim.2008.01.001 – ident: e_1_2_5_12_1 doi: 10.1002/bit.26360 – ident: e_1_2_5_46_1 – ident: e_1_2_5_71_1 doi: 10.1002/jps.24054 – ident: e_1_2_5_69_1 doi: 10.1002/btpr.2397 – ident: e_1_2_5_27_1 – ident: e_1_2_5_43_1 doi: 10.1002/prot.24388 – ident: e_1_2_5_62_1 – ident: e_1_2_5_68_1 doi: 10.1002/bit.22494 – ident: e_1_2_5_42_1 doi: 10.1136/thoraxjnl-2014-206719 – ident: e_1_2_5_59_1 doi: 10.1074/jbc.272.24.15270 – ident: e_1_2_5_23_1 – ident: e_1_2_5_45_1 doi: 10.1002/jps.24642 – ident: e_1_2_5_72_1 doi: 10.1016/j.xphs.2016.02.029 – ident: e_1_2_5_38_1 doi: 10.1016/j.chroma.2014.03.010 – ident: e_1_2_5_54_1 doi: 10.1111/j.1365-2516.2009.02039.x – ident: e_1_2_5_55_1 doi: 10.1111/hae.12127 – ident: e_1_2_5_2_1 doi: 10.1016/0022-1759(86)90481-3 – volume: 5 start-page: 1353 year: 1999 ident: e_1_2_5_33_1 article-title: Immunogenicity of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) products in patients undergoing combination therapy with GM‐CSF publication-title: Clin Cancer Res. contributor: fullname: Wadhwa M – ident: e_1_2_5_75_1 doi: 10.1007/s40259-013-0018-5 – volume: 48 start-page: 347 year: 2000 ident: e_1_2_5_77_1 article-title: Epitope spreading: a mechanism for progression of autoimmune disease publication-title: Archivum Immunologiae Et Therapiae Experimentalis. contributor: fullname: Tuohy VK – ident: e_1_2_5_36_1 doi: 10.1002/bit.25158 – volume: 17 start-page: 34 year: 2004 ident: e_1_2_5_15_1 article-title: A risk‐based approach to immunogenicity concerns of therapeutic protein products publication-title: Biopharm Int. contributor: fullname: Rosenberg AS – ident: e_1_2_5_22_1 – ident: e_1_2_5_7_1 – ident: e_1_2_5_70_1 doi: 10.1002/btpr.2455 – ident: e_1_2_5_18_1 doi: 10.1002/bit.25647 – ident: e_1_2_5_39_1 doi: 10.1016/0167-4838(92)90062-I – ident: e_1_2_5_47_1 – ident: e_1_2_5_30_1 doi: 10.1042/BJ20090272 – year: 2016 ident: e_1_2_5_41_1 article-title: Specific immune response to phospholipase B‐like2 protein, a host cell impurity in lebrikizumab clinical material publication-title: AAPS J. contributor: fullname: Fischer SK – ident: e_1_2_5_16_1 doi: 10.1016/j.biotechadv.2007.01.007 – ident: e_1_2_5_35_1 doi: 10.1002/btpr.50 – ident: e_1_2_5_61_1 – ident: e_1_2_5_52_1 doi: 10.1002/bit.23217 – ident: e_1_2_5_34_1 doi: 10.1002/biot.201100479 – ident: e_1_2_5_66_1 – ident: e_1_2_5_31_1 doi: 10.1128/JCM.00373-09 – ident: e_1_2_5_6_1 – ident: e_1_2_5_3_1 – ident: e_1_2_5_20_1 doi: 10.1111/j.1651-2227.1986.tb10357.x – ident: e_1_2_5_53_1 doi: 10.1111/j.1538-7836.2005.01367.x – ident: e_1_2_5_58_1 doi: 10.1074/jbc.M500765200 – ident: e_1_2_5_25_1 doi: 10.1056/NEJM199309023291001 – ident: e_1_2_5_9_1 doi: 10.1002/bit.22304 |
| SSID | ssj0008062 |
| Score | 2.5317476 |
| SecondaryResourceType | review_article |
| Snippet | In the 40‐year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at... In the 40-year history of biopharmaceuticals, there have been a few cases where the final products contained residual host cell protein (HCP) impurities at... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 828 |
| SubjectTerms | Animals Biological activity Biological Products - analysis Biopharmaceuticals Chinese Hamster Ovary proteins CHO Cells Chromatography, Liquid clinical responses Cricetinae Cricetulus Enzyme-Linked Immunosorbent Assay Homology host cell proteins Humans Immunogenicity Impurities Inserts Organic chemistry product stability Proteins Proteins - analysis Tandem Mass Spectrometry |
| Title | Experience with host cell protein impurities in biopharmaceuticals |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fbtpr.2640 https://www.ncbi.nlm.nih.gov/pubmed/29693803 https://www.proquest.com/docview/2111072167 https://search.proquest.com/docview/2030921536 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB6KJz34fkSrRPHgJTXJZje7eLJqKYIiYqEHIWSbDRYxLW168dc7kzR9KIJ4S9gNm52dyXwz2f0G4NyEWrueSRziLHSoxpWjkkA5UoQ9j2tsFnQ4-eFRtDvBfZd3a3BVnYUp-SFmCTeyjOJ7TQYe6_HlnDRU58NRA905xeseC2k71-3znDpKukUxUYTjwkEdlBWrkOtfzp5c9kU_AOYyXi0cTmsDXqtXLfeZvDcmuW70Pr-xOP5zLpuwPgWi9nWpOVtQM9k2rC3QE-5Ac86DbFO-1qYTITal-u2C3qGf2f2PIZW_w3DbxjvdHwzfFnPk413otO5ebtrOtOaC02PKdR3uSZOmAYsDkTJD1aaUn4bKU1J7oQlCN_FjhCwsCAzjspcYhgEVR4ygMFQ0JmV7sJINMnMAtpIpVZOJuVYCXaXWPk9VYDiXcaJ4GltwVkk_GpbUGlFJouxHJJCIBGJBvVqXaGpd4wiDVo943URowemsGe2CJBBnZjDBPvTvCPEMExbsl-s5G8VXAjXCZRZcFKvy-_BR8-XpmS4O_971CFYRVclyT28dVvLRxBwjcsn1SaGiXwxx6Yg |
| link.rule.ids | 315,783,787,1378,27937,27938,46307,46731 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLYmOAAH3o_yLIgDl25t06SJxIXXNJ5C05C4oKpZUzEhugm2C78eu103BkJC3FolVRrHrj-7yWeAQxNq7XomcYiz0KEaV45KAuVIEbY9rrFZ0OHk2zvReAiuHvljBY7LszAFP8Qo4UaWkX-vycApIV0bs4bqfu-tiv4cA_ZpNHdGZnneHJNHSTcvJ4qAXDiohbLkFXL92ujRSW_0A2JOItbc5dQX4Kl82WKnyUt10NfV9sc3Hsf_zmYR5odY1D4plGcJKiZbhrkvDIUrcDqmQrYpZWvToRCbsv12zvDQyezOa48q4GHEbeOd7nR7z1_T5O-r8FC_aJ01nGHZBafNlOs63JMmTQMWByJlhgpOKT8Nlaek9kIThG7ix4haWBAYxmU7MQxjKo4wQWG0aEzK1mAq62ZmA2wlUyooE3OtBHpLrX2eqsBwLuNE8TS24KAUf9Qr2DWigkfZj0ggEQnEgu1yYaKhgb1HGLd6RO0mQgv2R81oGiSBODPdAfah30cIaZiwYL1Y0NEovhKoEi6z4Chflt-Hj05b90262Px71z2YabRub6Kby7vrLZhFkCWLLb7bMNV_G5gdBDJ9vZvr6yeebu2h |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7CFkJ6SJtHE7d5uKWHXrxrWw9L9JQ0WfJoQwgJ7CFgLFsiS6nXbLyX_vrO2OvdpKVQerORjKzRjOebsfQNwEebGBNGtgiIszCgGleBLrgOlEzySBhslnQ4-duVPLvjFyMxWoHP3VmYlh9ikXAjy2i-12TgVeEGS9JQU1fTPrpzjNdfcImqSojoZskdpcKmmijicRmgEqqOViiMB4tHnzujPxDmc8DaeJzhK7jv3rXdaPK9P6tNP__5G43jf07mNazPkah_1KrOBqzYchNePuEn3ILjJRGyTwlbn46E-JTr9xt-h3Hpj39UVP8O420f78x4Uj08TZI_bsPd8PT2y1kwL7oQ5EyHYSAiZZ3jLOPSMUvlpnTsEh1pZaLE8iQs4gwxC-PcMqHywjKMqASCBI2xorWOvYFeOSntLvhaOSonkwmjJfpKY2LhNLdCqKzQwmUefOikn1Ytt0basijHKQkkJYF4sNetSzo3r8cUo9aIiN1k4sH7RTMaBkkgK-1khn3o5xECGiY92GnXczFKrCVqRMg8-NSsyt-HT49vr2_o4u2_dz2E1euTYfr1_OryHawhwlLt_t496NXTmd1HFFObg0ZbfwHrEOxQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Experience+with+host+cell+protein+impurities+in+biopharmaceuticals&rft.jtitle=Biotechnology+progress&rft.au=Vanderlaan%2C+Martin&rft.au=Zhu-Shimoni%2C+Judith&rft.au=Lin%2C+Sansan&rft.au=Gunawan%2C+Feny&rft.date=2018-07-01&rft.eissn=1520-6033&rft.volume=34&rft.issue=4&rft.spage=828&rft_id=info:doi/10.1002%2Fbtpr.2640&rft_id=info%3Apmid%2F29693803&rft.externalDocID=29693803 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=8756-7938&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=8756-7938&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=8756-7938&client=summon |